| 000 | 01813 a2200541 4500 | ||
|---|---|---|---|
| 005 | 20250516164031.0 | ||
| 264 | 0 | _c20150202 | |
| 008 | 201502s 0 0 eng d | ||
| 022 | _a1476-5497 | ||
| 024 | 7 |
_a10.1038/ijo.2013.149 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aLean, M E J | |
| 245 | 0 | 0 |
_aTolerability of nausea and vomiting and associations with weight loss in a randomized trial of liraglutide in obese, non-diabetic adults. _h[electronic resource] |
| 260 |
_bInternational journal of obesity (2005) _cMay 2014 |
||
| 300 |
_a689-97 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Multicenter Study; Randomized Controlled Trial | ||
| 650 | 0 | 4 | _aAdolescent |
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 |
_aAnti-Obesity Agents _xadverse effects |
| 650 | 0 | 4 | _aBody Mass Index |
| 650 | 0 | 4 | _aDose-Response Relationship, Drug |
| 650 | 0 | 4 | _aDouble-Blind Method |
| 650 | 0 | 4 | _aDrug Administration Schedule |
| 650 | 0 | 4 |
_aEurope _xepidemiology |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 |
_aGlucagon-Like Peptide 1 _xadverse effects |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aLiraglutide |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 |
_aNausea _xchemically induced |
| 650 | 0 | 4 |
_aObesity _xdrug therapy |
| 650 | 0 | 4 | _aQuality of Life |
| 650 | 0 | 4 | _aSeverity of Illness Index |
| 650 | 0 | 4 | _aTreatment Outcome |
| 650 | 0 | 4 |
_aVomiting _xchemically induced |
| 650 | 0 | 4 |
_aWeight Loss _xdrug effects |
| 700 | 1 | _aCarraro, R | |
| 700 | 1 | _aFiner, N | |
| 700 | 1 | _aHartvig, H | |
| 700 | 1 | _aLindegaard, M L | |
| 700 | 1 | _aRössner, S | |
| 700 | 1 | _aVan Gaal, L | |
| 700 | 1 | _aAstrup, A | |
| 773 | 0 |
_tInternational journal of obesity (2005) _gvol. 38 _gno. 5 _gp. 689-97 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1038/ijo.2013.149 _zAvailable from publisher's website |
| 999 |
_c23001359 _d23001359 |
||